Articles Tagged With:
-
Utility of Serial Coronary Calcium Scores
Researchers determined recently that if serial scans are performed, the most recent scan should be used for risk assessment, and the degree of CT calcium score progression adds no further prognostic information.
-
A New Risk Score for Stroke in Atrial Fibrillation
A new, simpler score for stroke risk prediction in atrial fibrillation patients uses biomarkers to supplant many clinical variables and outperforms the CHA2DS2-VASc score in two large cohorts.
-
Orbiting the Truth of Heart Failure Incidence and Implications in Those with Prevalent Atrial Fibrillation
Patients presenting with atrial fibrillation are at elevated risk for the development of heart failure, typically with preserved ejection fraction, which is associated with increased risk of death and hospitalization.
-
NOACs in Patients Requiring Anticoagulation Post-PCI
In patients with atrial fibrillation post-percutaneous coronary intervention with stent placement, recently studied regimens conferred a significantly lower risk of clinically important bleeding compared to standard triple therapy with full-dose warfarin.
-
Life Safety Code 2012: Changes You Need to Know
Does your hospital have what it takes to comply with CMS Hospital CoPs? -
Sacubitril/Valsartan Associated with Reduced Risk of Hyperkalemia
\In a secondary analysis of the PARADIGM-HF trial, the risk of severe hyperkalemia in heart failure patients taking a mineralocorticoid receptor antagonist was lower among patients treated with sacubitril/valsartan compared to those receiving enalapril.
-
Zika Virus Infection and Guillain-Barré Syndrome: The Evidence Grows
A recent Zika outbreak in Colombia was associated with a significant increase in Guillain-Barré syndrome (GBS) rates, with laboratory evidence of definite or probable Zika infection in more than half of the GBS cases.
-
Early Initiation of Continuous Renal Replacement Therapy May Reduce Mortality in Patients Who Require Dialysis
Initiation of continuous renal replacement therapy for patients with Kidney Disease: Improving Global Outcomes stage 2 renal failure reduced 90-day all-cause mortality.
-
Bezlotoxumab Injection (Zinplava)
The FDA has approved a selective, fully human monoclonal antibody directed at Clostridium difficilie toxin B. Binding of toxin B neutralizes its toxic effect. Bezlotoxumab is marketed as Zinplava.
-
Fecal Transplant vs. Oral Vancomycin Taper for Recurrent Clostridium difficile Infection
In a small randomized, controlled trial that compared fecal microbiota transplant (FMT) administered by enema to a six-week oral vancomycin taper, FMT was not more effective for patients with recurrent Clostridium difficile infection.